Quarterly Financial Results for Q1 of FY 2026-27

Sun Pharmaceutical Industries Limited SUN HOUSE, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 Website: www.sunpharma.com Email: secretarial@sunpharma.com CIN: L24230GJ1993PLC019050 31 July 2026 National Stock Exchange of India Limited BSE Limited NSE Code: SUNPHARMA BSE Code: 524715 Outcome of the Board Meeting held today, i.e., 31 July 2026 Further to the communication dated 10 July 2026, this is to inform that the Board of Directors of the Company, at its meeting held today, has, inter alia, 1. Approved Quarterly Financial Results The Unaudited Standalone and Consolidated Financial Results for Q1 of FY 2026-27, as approved pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) along with the Limited Review Report, are annexed herewith as Annexure A. 2. Press Release and Earnings Presentation The press release outlining key updates for Q1 of FY 2026-27 is annexed herewith as Annexure B. It will be released soon after this communication. Also enclosed herewith is the Earnings Presentation as Annexure C. The Board Meeting, which commenced at 10:50 AM, is ongoing and has been temporarily adjourned for a break and will resume for consideration of other agenda items. The outcome of the remaining matters, if any, shall be submitted upon conclusion of the meeting. For Sun Pharmaceutical Industries Limited (Anoop Deshpande) Company Secretary and Compliance Officer ICSI Membership No.: A23983 Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA Reaching People. Touching Lives Annexure A SR BC & CO LLP 12th Floor, The Ruby 29 Senapati Bapat Marq Dadar (West) Chartered Accountants Mumbai -400 028, India Tel :+912268198000 Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors Sun Pharmaceutical Industries Limited 1. We have reviewed the accompanying statement of unaudited standalone financial results of Sun Pharmaceutical Industries Limited (the "Company") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). 2. The Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For S R B C & CO LLP Chartered Accountants p:ration number: 324982E/E300003 t-'7 per Amit Singh Partner Membership No.: 408869 UDIN: .2.64DB-g69LF-5C.DS347 G Place: Mumbai Date: July 31, 2026 SR BC & CO LLP, a Limited L.ab1lity Partnership with LLP Identity No. AAB-431B Reqd. Office· 22. Cam,1c Street. Block 'B, 3rd Floor, Kolkata-700 016 Sun Pharmaceutical Industries Limited Registered Office: Sun Pharma Advanced Research Centre, Tandalja, Vadodara -390012. Corporate Office: Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai -400063 Tel.: +91 22 4324 4324. CIN: L24230GJ1993PLC019050, Website: www.sunpharma.com Statement of Unaudited Standalone Financial Results for the Quarter ended June 30, 2026 (f in Million) Quarter ended Year ended Particulars 30.06.2026 31.03.2026 30.06.2025 31.03.2026 Unaudited Audited Unaudited Audited I Revenue from operations a. Revenue from contracts with customers 56,413.1 48,872.7 55,592.7 206,090.2 b. Other operating revenues 998.2 366.1 356.1 1,456.2 Total revenue from operations (I) 57,411.3 49,238.8 55,948.8 207,546.4 II Other income 1,401.7 629.3 1,037.1 4,193.3 Ill Total income (1+11) 58,813.0 49,868.1 56,985.9 211,739.7 IV Expenses Cost of materials consumed 12,397.4 12,286.6 9,979.3 43,832.7 Purchases of stock-in-trade 2,750.4 3,119.1 3,282.5 13,915.2 Changes in inventories of finished goods, stock-in-trade and work-in-progress (192.2) (3,453.7) 930.2 (3,058.3) Employee benefits expense 8,309.3 7,039.9 7,389.2 29,113.0 Finance costs 2,784.8 2,169.2 2,384.2 9,478.4 Depreciation and amortisation expense 3,079.2 3,259.7 3,109.2 13,117.2 Other expenses 16,273.3 22,185.9 17,168.2 75,507.9 Net (gain)/ loss on foreign currency transactions (1,769.0) (5,228.7) (1,895.9) (13,571.0) Total expenses (IV) 43,633.2 41,378.0 42,346.9 168,335.1 V Profit/ (loss) before exceptional items and tax (Ill-IV) 15,179.8 8,490.1 14,639.0 43,404.6 VI Exceptional items (Refer Note 3 and 4) 315.3 - 2,876.4 5,463.4 VII Profit/ (loss) before tax (V-VI) 14,864.5 8,490.1 11,762.6 37,941.2 VIII (i) Tax expense/ (credit) 3,792.4 2,150.2 5,317.1 13,363.2 (ii) Tax expense/ (credit) -Exceptional (Refer Note 3 and 4) (79.3) 252.9 (1,005.1) (1,656.2) IX Profit I (loss) for the period (VII-VIII) 11,151.4 6,087.0 7,450.6 26,234.2 X Other comprehensive income (OCI) a. (i) Items that will not be reclassified to profit or loss 42.2 (94.3) (28.8) (64.4) (ii) Income tax relating to items that will not be reclassified to profit or loss (10.6) 26.1 105 16.2 b. (i) Items that may be reclassified to profit or loss 1,886.5 (1,658.3) 330.6 (2,862.8) (ii) Income tax relating to items that may be reclassified to profit or loss (474.8) 299.6 (115.5) 720.5 Total other comprehensive income (a+b) (X) 1,443.3 (1,426.9) 196.8 (2,190.5) XI Total comprehensive income for the period (IX+X) 12,594.7 4,660.1 7,647.4 24,043.7 XII Paid-up equity share capital -face value ~ 1 each 2,399.3 2,399.3 2,399.3 2,399.3 XIII Other equity 221,308.3 XIV Earnings per equity share off 1 each (not annualised for quarters) ~ (Basic) 4.6 2.5 3.1 10.9 ~ (Diluted) 4.6 2.5 3.1 10.9 See accompanying notes to the unaudited standalone financial results Research and development expenses incurred (included above) 4,635.9 6,797.0 6,146.9 21,635.0 SIGNED FOR IDENTIF [Showing first 8,000 characters — download PDF for full document]